Vantage Point: Another look at marketing data

Richard Vanderveer
Richard Vanderveer

For the discontinuous healthcare world of 2013 and beyond, it can't hurt to take another look at the levels of data that make up the marketing-information bull's-eye:

Primary Data—We all know that this term refers to information collected directly from appropriate respondents to deal with the marketing issue at hand.

Got a question? Conduct some focus groups, field a survey, etc., and you will find out the answer you need. Right away. Right on target. Simple.

Secondary Data—The pharmaceutical industry has always had a wealth of this kind of information. Prescription data, promotional data, de-identified longitudinal patient level data, etc., with more on the way. While by definition such data are not collected to answer a specific marketing question, their analysis has long given healthcare manufacturers valuable insights related to our marketing issues.

Tertiary Data—You haven't heard this term used before, because I just made it up! In my parlance, it refers to “external drivers” that might well have significant impact on determining the right answer to your marketing question. Such data include changes in US demographics, the increasing utilization of mobile devices, the number of new lives eligible for insurance coverage under Obamacare, the worsening doctor shortage and other disparate pieces of information that need to be considered in making sound marketing decisions for the future.

While tertiary data, if considered at all, might previously have been considered less-than-central for making marketing decisions, in a changing healthcare landscape, they must increasingly be thought of as comprising an essential backdrop against which all other data must be viewed.


Richard Vanderveer is chief solutions officer, rbV3.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.